[Immunotherapy of malignant melanoma. New prospects].
Malignant melanoma is an immunogenic tumor which can induce host humoral and cellular responses, and is a good model for development of anti-cancer immunotherapy. During the last decade systemically-administrated interferon and interleukin-2 have been used. Advances in immunology and molecular biology could allow a more specific and active immunotherapy. Perspectives include chemo-immunotherapy, monoclonal antibodies alone or in combination with cytotoxic agents, adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL), gene therapy designed to increase tumor immunogenicity, and active immunotherapy with vaccines.
Hebbar
M
M
Service de l'hôpital de jour, centre Oscar-Lambret, Lille, France.
Vanlemmens
L
L
Lecomte
S
S
Bonneterre
J
J
D000818:Animals; D004195:Disease Models, Animal; D005544:Forecasting; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology; D014611:Vaccination
Immunothérapie du mélanome malin. Nouvelles perspectives.